Budget Range
Min
€1,500
Average
€48,313
Max
€209,986
Role Distribution
Sector Distribution
Budget by Sector (€)
Projects (44)
P
Integrated Services for Infectious Disease Outbreak Research
HORIZON.1.3101046133
€209,986
P
Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
Health101096362
€106,073
P
Catalysis for Cancer Treatment.
HORIZON.1.1101118999
€106,040
P
Framework to IMPROVE the Integration of Patient Generated Health Data to Facilitate Value Based Healthcare
Health101132847
€103,138
P
Genome control by DNA-looping motors: from folding to function
HORIZON.1.1101224824
€100,000
P
COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE
Health101103746
€99,841
P
Preclinical in vitro Models for the Replacement, Reduction and Refinement of Mouse Models in Preclinical Studies (PRIM-TECH3R)
Research Infrastructures101188158
€90,000
P
From fragments to high affinity binders interfacing integrated structural biology, medicinal chemistry and artificial intelligence
Research Infrastructures101094131
€82,651
P
A European-wide foundation to accelerate Data-driven Cancer Research
Research Infrastructures101058427
€78,145
C
THE STRONG-AYA INITIATIVE: IMPROVING THE FUTURE OF YOUNG ADULTS WITH CANCER
Health101057482
€72,350
P
Implementing value-based oncology care at European cancer hospitals: An AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time
Health101095245
€69,530
P
Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers
Health101137233
€68,068
P
Prediction and prevention of late effects in AYA cancer survivors – An effort to understand, predict and prevent late effects in AYAs 15-39 years of age, with a focus on fertility and gonadal toxicity
Health101214879
€63,291
P
Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors
Health101104684
€59,988
P
PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials
Health101104269
€59,687
P
PREFERABLE-II - Personalised Exercise-Oncology for improvement of supportive care: a super umbrella trial to demonstrate the (cost)effectiveness of live-remote exercise in cancer survivors
Health101057059
€59,255
P
Patient-centred, evidence-based late effect screening and follow-up care of survivors of adolescent and young adult cancer
HORIZON.2.1101213107
€57,702
P
First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma
Health101104801
€55,777
P
A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR PATIENTS WITH HIGH RISK RETROPERITONEAL SARCOMA
Health101103843
€49,719
C
Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation, and clinical management
HORIZON.1.2101227105
€46,975
P
Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research
Research Infrastructures101131669
€39,999
P
From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network
MSCA (Marie Skłodowska-Curie)101081481
€37,632
P
Deconstructing adaptive evolution of metastasis
MSCA (Marie Skłodowska-Curie)101169223
€35,166
P
A Coordination and Support Action to prepare UNCAN.eu platform
Health101069496
€29,896
P
DNA Repair State Machines
MSCA (Marie Skłodowska-Curie)101073485
€27,641
P
Doctoral Network for a Shared Excellence of Fluorescent Lifetime Imaging Microscopy in Biomedical Applications
MSCA (Marie Skłodowska-Curie)101073507
€27,435
P
DNA replication at the heart of cell fate decisions and cancer development
MSCA (Marie Skłodowska-Curie)101072903
€26,503
C
Causes and consequences of aberrant mRNA translation in cancer
HORIZON.1.1101141245
€25,000
C
Paradoxical activation of oncogenic signaling as a cancer treatment strategy.
HORIZON.1.1101141685
€25,000
C
Reversing T cell dysfunction in cancer by multimodal genetic screening
HORIZON.1.1101054465
€24,994
P
ERA Chair Life Sciences Program to EmpoweR moleculAr aNd struCtural biology initiativEs at UPAT
Widening Participation101087215
€24,990
C
Location, location, location: the (re-)positioning of regulatory elements in the mammalian genome.
HORIZON.1.1101054449
€24,939
C
Deep genetics to study and uncover ‘hidden’ biology
ERC (European Research Council)101142218
€24,516
P
PUBLIC ENGAGEMENT IN RESEARCH INFRASTRUCTURES FOR MISSION CANCER: MANAGING COMPLEXITY OF EMERGING TECHNOLOGIES
Health101216808
€23,623
C
Single-molecule visualization of transcription dynamics to understand regulatory mechanisms of cofactors
HORIZON.1.1101169447
€20,000
P
IDIBAPS Doctoral programme Yielding Novel Advancements in Medicine and Innovative Solutions
MSCA (Marie Skłodowska-Curie)101217395
€15,840
P
TWINNING FOR A EUROPEAN CONSORTIUM OF RECTAL CANCER RESEARCH INSTITUTIONS THROUGH STEPPING UP SCIENTIFIC, TECHNOLOGICAL AND INNOVATION EXCELLENCE OF IORS
HORIZON.4.1101079217
€15,000
C
Disentangling the relationship between autoimmunity, cancer treatment, and risk of subsequent breast cancer
HORIZON.1.1101221376
€14,997
C
Why do transcription factors bind what they bind when they bind?
HORIZON.1.1101162742
€14,967
C
Evolution of T cell reactivity against somatic mutations across human colon cancer stages with single-cell genomics and synthetic T cell specificity screening
MSCA (Marie Skłodowska-Curie)101208803
€2,171
P
Role of astrogliosis in the recurrence of brain tumors after microsurgical resection
MSCA (Marie Skłodowska-Curie)101061921
€2,097
C
Understanding aneuploidy tolerance in cancer by studying early embryogenesis
MSCA (Marie Skłodowska-Curie)101068843
€1,904
P
Defining the role of the tumor microenvironment in treatment resistance of OVArian cancer through patient-Derived EXplants (OVADEX)
MSCA (Marie Skłodowska-Curie)101064216
€1,759
C
Using senolytic agents to suppress the toxicity of chemotherapy
HORIZON.1.1101213120
€1,500